Encysive nearly doubles workforce preparing for launch of Thelin

By Ted A. Knutson

Washington, Nov. 29 - Encysive Pharmaceuticals Inc. has increased the number of its employees to 215 from the 117 workers it had on Dec. 31, 2004 in preparation for the commercialization of Thelin (sitaxsentan sodium), an oral small molecule drug for the treatment of pulmonary arterial hypertension, according to a company news release Tuesday.

The Food and Drug Administration Prescription Drug User Fee Act target action date for Thelin is March 24. The drug is also under review by regulatory authorities Europe.

The current workforce includes a 51-person sales team.

Encysive said the additional workers will not have a material impact on current guidance for expenses for 2005 but will materially increase expenses in future periods.

Encysive is a Houston-based biotech company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.